Long-term measles antibody profiles following different vaccine schedules in China, a longitudinal study

Qianli Wang, Wei Wang, Amy K. Winter, Zhifei Zhan, Marco Ajelli, Filippo Trentini, Lili Wang, Fangcai Li, Juan Yang, Xingyu Xiang, Qiaohong Liao, Jiaxin Zhou, Jinxin Guo, Xuemei Yan, Nuolan Liu, C. Jessica E. Metcalf, Bryan T. Grenfell and Hongjie Yu ()
Additional contact information
Qianli Wang: Fudan University
Wei Wang: Key Laboratory of Public Health Safety, Ministry of Education
Amy K. Winter: University of Georgia
Zhifei Zhan: Hunan Provincial Center for Disease Control and Prevention
Marco Ajelli: Indiana University School of Public Health
Filippo Trentini: Bocconi University
Lili Wang: Key Laboratory of Public Health Safety, Ministry of Education
Fangcai Li: Hunan Provincial Center for Disease Control and Prevention
Juan Yang: Key Laboratory of Public Health Safety, Ministry of Education
Xingyu Xiang: Hunan Provincial Center for Disease Control and Prevention
Qiaohong Liao: Key Laboratory of Public Health Safety, Ministry of Education
Jiaxin Zhou: Key Laboratory of Public Health Safety, Ministry of Education
Jinxin Guo: Key Laboratory of Public Health Safety, Ministry of Education
Xuemei Yan: Key Laboratory of Public Health Safety, Ministry of Education
Nuolan Liu: Key Laboratory of Public Health Safety, Ministry of Education
C. Jessica E. Metcalf: Princeton University
Bryan T. Grenfell: Princeton University
Hongjie Yu: Fudan University

Nature Communications, 2023, vol. 14, issue 1, 1-8

Abstract: Abstract Characterizing the long-term kinetics of maternally derived and vaccine-induced measles immunity is critical for informing measles immunization strategies moving forward. Based on two prospective cohorts of children in China, we estimate that maternally derived immunity against measles persists for 2.4 months. Following two-dose series of measles-containing vaccine (MCV) at 8 and 18 months of age, the immune protection against measles is not lifelong, and antibody concentrations are extrapolated to fall below the protective threshold of 200 mIU/ml at 14.3 years. A catch-up MCV dose in addition to the routine doses between 8 months and 5 years reduce the cumulative incidence of seroreversion by 79.3–88.7% by the age of 6 years. Our findings also support a good immune response after the first MCV vaccination at 8 months. These findings, coupled with the effectiveness of a catch-up dose in addition to the routine doses, could be instrumental to relevant stakeholders when planning routine immunization schedules and supplemental immunization activities.

Date: 2023
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-023-37407-x Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-37407-x

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-37407-x

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().